all-trans retinoid acid

ApprovedSmall molecule

all-trans retinoid acid is one of 99 small molecule programs targeting Acute Promyelocytic Leukemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Promyelocytic LeukemiaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Immune ThrombocytopeniaActive, not recruiting

Acute Promyelocytic LeukemiaApproved

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Immune ThrombocytopeniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

31 2

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

28 4

Empaveli

Gilead

Phase 3

4 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 6

Zarnestra

KKura Oncology, Inc.

Phase 3

9 7

Decadron

AAspen Global Incorporated

Phase 3

5 8

Astplayer

AAstex Pharmaceuticals, Inc.

Phase 3

3 9

all-trans retinoid acid

UUniversity of Ulm

Approved

1 10

Homoharringtonine

Ascentage Pharma Group Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immune Thrombocytopenia2 trials

Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia

Completed·—··NCT01668615·35 enrolled

All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Withdrawn·SShandong University·Phase 3·NCT01882127

Acute Promyelocytic Leukemia1 trial

AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

Unknown status·TTechnische Universität Dresden·Phase 4·NCT00180128·80 enrolled

Refractory AML1 trial

Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)

Completed·UUniversity of Ulm·Phase 2·NCT00143975·95 enrolled

Acute Myeloid Leukemia1 trial

Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result

Completed·UUniversity of Ulm·Phase 3·NCT00146120·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for all-trans retinoid acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — all-trans retinoid acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for all-trans retinoid acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Ulm company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Ulm

all-trans retinoid acid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immune Thrombocytopenia2 trials

Acute Promyelocytic Leukemia1 trial

Refractory AML1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News